Efficacy of Umbilical Cord-Derived Mesenchymal Stem Cells in the Treatment of Type 2 Diabetes Assessed by Retrospective Continuous Glucose Monitoring

In this randomized and placebo-controlled trial, a total of 73 patients were randomly assigned to receive intravenous infusion of umbilical cord-derived mesenchymal stem cells or placebo, three times at four-week intervals and followed up for 48 weeks.